Ireland
--:--IST
Starting soon Phase 4

Sivelestat Treatment for Postoperative Organ Protection in Type A Aortic Dissection

NCT07156656 · tracked via the Priya Life Science China tracker
Phase
Phase 4
Started
2025-09-01
Last updated
2025-09-05

Condition(s) studied

Type A Aortic DissectionOrgan Failure, Multiple

Investigational drug(s) / intervention(s)

Conventional treatmentSivelestat sodium →Placebo

Conventional treatment: Beside the using of Sivelestat Sodium or placebo, all postoperative care will adhere to each center's standard protocols for type A aortic dissection.

Sivelestat sodium: The daily dose (4.8 mg/kg) is diluted in 48 mL of 0.9 % saline and administered as a continuous intravenous infusion over 24 hours at 2 mL/h (equivalent to 0.2 mg/kg/h) for 72 consecutive hours.

Placebo: An equal volume of placebo-containing only the excipients of sivelestat sodium and diluted to 48 mL with 0.9 % saline-will be infused at 2 mL/h for 72 consecutive hours.

Study summary

The goal of this multicenter, double-blind, randomized controlled trial is to learn if sivelestat sodium (Siv) can protect the organ function in patients suffered operation for acute type A aortic dissection. The main questions it aims to answer are:

* Can the 3-day-treatment of Siv enlarge the Day-0-to-Day-5 drop in the organ-health score (SOFA score)?
* Can this treatment significantly shrink the area under the SOFA curve from first dose to Day 5?
* Can this treatment significantly improve the end of patients in 28 days (clinical outcomes)? Researchers will compare drug Siv to a placebo (a look-alike substance that contains no drug) to see if drug Siv works.

Participants will:

* Take drug Siv or the placebo through vein continuously for 72 hours
* Receiving regular intensive care in ICU after the operation

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age 18-75 years inclusive. 2. Written informed consent obtained before participation. 3. Confirmed acute Stanford type A aortic dissection scheduled for surgical repair. Exclusion Criteria: 1. Life expectancy ≤ 48 hours. 2. Pregnant or lactation. 3. Severe pre-operative liver dysfunction: Child-Turcotte-Pugh score 10-15. 4. Severe pre-operative renal dysfunction: acute or chronic kidney injury meeting criteria for renal-replacement therapy. 5. Confirmed COPD or asthma. 6. Immunosuppression: long-term or \> 2 weeks continuous systemic corticosteroids. 7. Concomitant or anticipated use of immunomodulators (Xue-Bi-Jing injection, thymosin, IVIG). 8. Medical or psychological condition that would interfere with study participation, assessment, or outcomes.

Primary outcome measure(s)

  • ΔSOFA5 — from the entry of ICU(baseline, post-operatively) to the fifth day in ICU(the fifth day after the first dose)
    ΔSOFA5 is defined as the decrease level of SOFA(Sequential Organ Failure Assessment) score from baseline to the fifth day. SOFA score ranges from 0\~24, the higher the score, the poorer the functionality of multiple organs.

Trial sites (6)

FacilityCityRegionStatus
The First Affiliated Hospital of Anhui Medical University Hefei Anhui
Fujian Provincial Hospital Fuzhou Fujian
Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences) (Guangdong Provincial People's Hospital Affiliated to Southern Medical University) Guangzhou Guangdong
The University of Hong Kong - Shenzhen Hospital Shenzhen Guangdong
The First Affiliated Hospital of Xi'an Jiao Tong University Xi'an Shaanxi
Changhai Hospital of Shanghai Shanghai Shanghai Municipality
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07156656 on ClinicalTrials.gov ↗ ← All trials in China